ArticleJournal of molecular medicine (Berlin, Germany)2025
Transcriptome profiling of human dermal MDPL fibroblasts reveals a characteristic molecular signature providing insights into pathogenic mechanisms.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The emerging perception that the mammalian dermis encloses fibroblasts with differing functional identities has profound implications for understanding a wide range of genetic pathological states, including aging. MDPL syndrome (mandibular hypoplasia, deafness, progeroid characteristics, and lipodystrophy; MIM #615381) is an extremely rare, genetic progeroid disorder. Patients reported variants in the POLD1 gene (NM_002691.3), encoding for the evolutionarily conserved catalytic subunit of DNA polymerase delta (Polδ). The protein is a critical enzyme reliable for synthesizing nascent DNA strands in the eukaryotic genome. Importantly, Polδ also serves to repair DNA lesions due to mutagen exposure. As the natural history of MDPL still remains poorly known, we have performed RNA sequencing analyses on human dermal fibroblasts (HDFs) of two MDPL patients, heterozygotes for p.Ser605del, compared to WT HDFs. The bioinformatic analyses identify differentially expressed transcripts related to the extracellular matrix of connective tissue and transduction signal markers. Successively, we shed light on the capacity of MDPL cells to respond to and repair DNA damage by comparing transcript levels between X-irradiated MDPL HDFs and non-irradiated ones. Importantly, the results allowed us to identify specific downregulated molecular traits in irradiated MDPL HDFs, including those genes closely involved in the mechanisms of DNA replication and repair. These data were further validated at the functional level, choosing four pivotal proteins (CDC6 (Cell Division Cycle 6), CLSPN (Claspin), XRCC3 (X-Ray Repair Cross Complementing 3), RAD51 (DNA repair protein RAD51 homolog 1)) involved in interconnected pathways ensuring genomic stability. This work provides critical insights into the pathogenesis and the regulatory mechanisms of MDPL syndrome and related diseases, paving the way for future therapeutic interventions. KEY MESSAGES: We identified a molecular signature in MDPL human dermal fibroblasts by transcriptomic profiling. We identified specific markers linked to the extracellular matrix of connective tissue and transduction signal markers. We ascertained in irradiated MDPL human dermal fibroblasts specific downregulated molecular traits, involved in the mechanisms of DNA replication and repair. We validated at functional and biochemical level specific those proteins involved in pathways ensuring genomic stability. The markers identified could be targeted for therapeutic intervention in MDPL syndrome and aging-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.